| Literature DB >> 16678414 |
Christopher M McBride1, Paul A Renhowe, Thomas G Gesner, Johanna M Jansen, Julie Lin, Sylvia Ma, Yasheen Zhou, Cynthia M Shafer.
Abstract
The 3-benzimidazol-2-yl-1H-indazole scaffold was developed as an alternate scaffold for our receptor tyrosine kinase (RTK) inhibitor program. In exploring the SAR of this series, it was discovered that a subset of these compounds potently inhibit the enzyme c-ABL. The SAR of these compounds is described.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16678414 DOI： 10.1016/j.bmcl.2006.04.043
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823